UVision IPO Faces Delays Amid Defense Stock Market Downturn

The recent decline in the valuation of public defense companies in Israel threatens to delay the much-anticipated initial public offering of UVision, controlled by Aaron Frenkel. Originally scheduled for August, the IPO has already been pushed to November. Investment banking giant JPMorgan is expected to lead the offering.

Valuation Gap and Strategic Dilemmas

Frenkel and the company are refusing to compromise on a valuation of less than $3.5 billion to $4 billion, nor are they willing to budge on the listing venue. While industry insiders note that the Tel Aviv Stock Exchange is well-suited for such an offering, Frenkel insists on launching the IPO in the United States. UVision aims to raise between $500 million and $600 million in primary capital.

"All options are being evaluated as market conditions evolve," representatives for UVision stated.

Part of the proceeds is earmarked to repay shareholder loans extended by Frenkel over the years, though the majority is intended for new product development and manufacturing expansion. The company's flagship product is the Hero-120 loitering munition, which has seen surging demand in recent global conflicts.

Market Pressures and Institutional Hesitation

Prior to the planned IPO, Frenkel attempted in at least two rounds to secure capital from institutional investors. However, institutional backers were only willing to value the company at $2.8 billion to $2.9 billion—even before the recent market correction affecting defense stocks. As a result, the company is also exploring the introduction of a foreign financial investor, similar to Fibrotex's strategy, which could entail a further postponement of the IPO.

Newly appointed Chief Financial Officer Eyal Rubin is leading the strategic review to assess the company's options, recognizing that reaching the desired valuation in the current climate will be challenging, particularly given the company's annual revenues of approximately $250 million.

The Next Vision Fallout

Publicly traded Next Vision has been among the hardest hit by the downturn on the Tel Aviv Stock Exchange, plunging 25% last week to a market cap of roughly 18 billion shekels—less than half its peak valuation. The sharp decline was triggered by an unusual move by American fund Fidelity, which decided to liquidate its entire stake acquired just 12 to 18 months ago, engaging Goldman Sachs to offload shares worth 1.3 billion shekels.